Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa)

Prostate

Volumn 40, Issue 4, 1999, Pages 256-260

  Sarkar, Fazlul H ^a   Li, Yiwei ^a   Sakr, Wael A ^a   Grignon, David J ^a   Madan, Shahi S ^a   Wood Jr , David P ^a   Adsay, Volkan ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Disease free survival; P21(WAF1); Prostatic carcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P21;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION;

ADENOCARCINOMA; AFRICAN CONTINENTAL ANCESTRY GROUP; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0032793571     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990901)40:4<256::AID-PROS7>3.0.CO;2-I     Document Type: Article

References (35)

1. American Cancer Society. Cancer facts and figures 1998. Atlanta: American Cancer Society, Inc.; 1998.
2. Krongrad A, Lai S, Vidal EM. The significance of changing trends in prostate cancer incidence and mortality. Semin Urol Oncol 1998;16:30-34.
3. Chiarodo A. National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res 1991;51:2498-2505.
4. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-552.
5. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118:804-818.
6. Biggs JR, Kraft AS. Inhibitors of cyclin-dependent kinase and cancer. J Mol Med 1995;73:509-514.
7. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 1993;75:805-816.
8. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinase. Nature 1993;366: 701-704.
9. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory sub-unit. Nature 1993;366: 707-710.
10. WAF1/CIP1 expression in the absence of p53. Oncogene 1994;9:3397-3406.
11. Halevy O, Novitch BG, Spicer DB, Skapk SX, Rhee J, Hannon GJ, Beach D, Lassar AB. Correlation of terminal cell-cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267:1018-1021.
12. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 1994;9:3389-3396.
13. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55:5187-5190.
14. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-1023.
15. Namba H, Hara T, Tukazaki T, Migita K, Ishikawa N, Ito K, Nagataki S, Yamashita S. Radiation-induced G1 arrest is selectively mediated by the p53-Waf1Cip1 pathway in human thyroid cells. Cancer Res 1995;55:2075-2080.
16. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75: 817-825.
17. el-Deiry WS, Harper JW, O'Conner PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-1174.
18. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-3395.
19. WAF1/CIP1 expression by p53-independent pathway. Oncogene 1996;12:1557-1564.
20. Chen YQ, Cipriano SC, Sarkar FH, Ware JL, Arenkiel JM. p53-independent induction of p21WAF1 pathway is preserved during tumor progression. Int J Oncol 1995;7:889-893.
21. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84: 3781-3784.
22. Gao X, Chen YQ, Wu N. Somatic mutations of WAF1/CIP1 gene in primary prostate cancer. Oncogene 1995;11:1395-1398.
23. Li YJ, Laurent-Puig P, Salmon RJ, Thomas G, Hamelin R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 1995;10:599-601.
24. Shimizu T, Miwa W, Nakamori S, Ishikawa O, Konishi Y, Sekiya T. Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn J Cancer Res 1996;87:275-278.
25. CIP1/WAF1 protein accumulation in head-and-neck cancer. Int J Cancer 1997;74:383-389.
26. WAF1) in normal and neoplastic prostate tissue. J Urol Pathol 1998;9:115-128.
27. WA1/CIP1 in human brain tumors. Oncogene 1995;11:2021-2028.
28. Byrne RL, Home CH, Robinson MC, Autzen P, Apakama I, Bishop RI, Neal DE, Hamdy FC. The expression of WAF1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997;79:190-195.
29. WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-1079.
30. Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-920.
31. Yang RM, Naitoh J, Murphy M, Wang H-J, Phillipson J, deKernion JB, Loda M, Reiter RE. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-945.
32. KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-1291.
33. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-752.
34. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 1994;369:574-578.
35. Gulbis JM, Kelman Z, Hurwitz J, O'Donnell M, Kuriyan J. Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell 1996;87:297-306.